Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Westin

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
JAMA Network Open|September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation TherapyChelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Head & Neck|June 1, 2018
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
American Journal of Hematology|February 21, 2019
Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphomaPaolo Strati, Seung Tae Lee, Purnima Teegavarupu, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Blood Advances|June 27, 2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, et al.
Advances in Radiation Oncology|November 18, 2024
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Penny Fang, Sonal S Noticewala, Susan Y Wu, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
JAMA Network Open|September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation TherapyChelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Leukemia & Lymphoma|August 9, 2021
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphomaLoretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, et al.
Nature Reviews. Clinical Oncology|September 20, 2017
Chimeric antigen receptor T-cell therapy - assessment and management of toxicitiesSattva S Neelapu, Sudhakar Tummala, Partow Kebriaei, et al.
Head & Neck|June 1, 2018
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Head & Neck|April 4, 2017
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphomaChelsea C Pinnix, Bouthaina S Dabaja, Sarah A Milgrom, et al.
American Journal of Hematology|February 21, 2019
Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphomaPaolo Strati, Seung Tae Lee, Purnima Teegavarupu, et al.
The Oncologist|April 15, 2017
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell LymphomaHun Ju Lee, Jorge E Romaguera, Lei Feng, et al.
Blood Advances|June 27, 2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, et al.
Advances in Radiation Oncology|November 18, 2024
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Penny Fang, Sonal S Noticewala, Susan Y Wu, et al.
Pageof 10